Muscle-Invasive Bladder Cancer: Is Radical Cystectomy Always Necessary?

Being told that bladder cancer has invaded the muscle is an important turning point in treatment.

After TURBT, a pathology report may show high-grade urothelial carcinoma invading the muscularis propria (detrusor muscle). This is termed muscle-invasive bladder cancer (MIBC) and generally corresponds to stage T2 or higher disease.

A common question at this stage is:

“Does muscle-invasive bladder cancer always mean that my bladder has to be removed?”

The answer is no—not in every patient. Radical cystectomy is a major curative treatment for MIBC, but appropriately selected patients may also be candidates for a bladder-preserving approach using maximal TURBT followed by chemotherapy and radiotherapy. Treatment selection requires careful staging and multidisciplinary assessment.

What Is Muscle-Invasive Bladder Cancer?

The bladder wall contains several layers. The muscularis propria, or detrusor muscle, is the thick muscle responsible for bladder contraction.

When bladder cancer has grown into this muscle layer, it is classified as muscle-invasive disease.

The distinction between T1 and T2 is particularly important:

T1: Cancer has invaded the connective tissue beneath the bladder lining but has not reached the detrusor muscle.

T2: Cancer has invaded the muscularis propria.

This distinction substantially changes the treatment strategy because muscle-invasive disease has a greater potential for regional and distant spread than non-muscle-invasive bladder cancer.

What Happens After TURBT Shows Muscle Invasion?

A TURBT pathology report showing muscle invasion is only one component of the evaluation.

Before deciding treatment, the clinical team needs to establish the extent of disease and assess the patient's suitability for different treatment options.

Evaluation generally considers:

• TURBT and histopathology findings
• Tumour stage and histological subtype
• Imaging for lymph-node or distant disease
• Kidney function
• General health and performance status
• Eligibility for systemic treatment
• Suitability for major surgery
• Possibility of bladder-preserving treatment
• Individual patient preferences

This is why a diagnosis of MIBC should ideally trigger comprehensive uro-oncological assessment rather than an automatic decision for surgery alone.

Is Radical Cystectomy the Standard Treatment?

Radical cystectomy with pelvic lymph-node dissection is one of the principal curative treatments for localised muscle-invasive bladder cancer.

Radical cystectomy involves removal of the urinary bladder together with an appropriate pelvic lymph-node dissection.

After bladder removal, a new pathway must be created for urine. This is called urinary diversion and may include an ileal conduit, orthotopic neobladder or another diversion depending upon the individual patient.

However, an important principle of modern bladder cancer treatment is:

Radical cystectomy should not automatically be viewed as surgery alone.

Systemic therapy before or after surgery can be an important component of the curative treatment pathway.

Why May Treatment Be Required Before Surgery?

Even when scans suggest that bladder cancer is confined to the bladder, microscopic cancer cells may already exist elsewhere in the body but remain too small to detect on conventional imaging.

This is one reason systemic treatment can be valuable.

For patients who are suitable candidates, cisplatin-based combination chemotherapy before radical cystectomy—neoadjuvant chemotherapy—has established survival benefit compared with surgery alone.

The perioperative treatment landscape is also evolving, with systemic and immunotherapy-based strategies increasingly incorporated into treatment pathways for selected patients.

Therefore, patients should ideally be assessed for systemic therapy before proceeding directly to cystectomy.

Can Muscle-Invasive Bladder Cancer Be Treated Without Removing the Bladder?

Yes, in appropriately selected patients.

A recognised curative-intent alternative is trimodality therapy (TMT).

This typically combines:

Maximal TURBT + Radiation Therapy + Concurrent Radiosensitising Chemotherapy

The objective is to eradicate the cancer while preserving a functioning urinary bladder.

Chemotherapy is important because it increases the effectiveness of radiotherapy. Evidence supports concurrent chemoradiation as a bladder-preserving treatment strategy for selected patients with MIBC.

Therefore, bladder preservation should not simply be considered “less treatment” than surgery. When appropriately delivered, it is a structured multimodality cancer treatment.

Who May Be Suitable for Bladder Preservation?

Not every patient with MIBC is an ideal candidate for trimodality therapy.

Patient selection is crucial.

Factors considered include the extent and location of the tumour, ability to achieve a satisfactory TURBT, bladder function, presence of associated carcinoma in situ, hydronephrosis, overall tumour burden and the patient's ability to undergo chemotherapy and radiotherapy and comply with intensive follow-up.

Evidence suggests that bladder-preserving treatment performs particularly well in appropriately selected patients, including those with more favourable local tumour characteristics.

The decision should therefore be individualised after discussion between uro-oncology, medical oncology and radiation oncology teams.

Does Bladder Preservation Mean the Bladder Can Never Be Removed?

No.

An essential part of a bladder-preservation programme is careful lifelong surveillance.

Patients require regular cystoscopy and appropriate imaging after treatment.

If invasive cancer persists or subsequently recurs within the bladder, salvage radical cystectomy may be required.

A patient considering bladder preservation should therefore understand both the potential benefit of retaining the bladder and the commitment to structured follow-up.

Radical Cystectomy or Bladder Preservation: Which Is Better?

There is no single answer that applies to every patient.

Radical cystectomy provides definitive surgical removal of the primary bladder tumour and allows comprehensive pathological assessment of the bladder and lymph nodes.

Trimodality therapy offers appropriately selected patients the possibility of maintaining their native bladder while still pursuing curative-intent treatment.

Importantly, high-quality randomised evidence directly comparing modern radical cystectomy with modern trimodality therapy remains limited. Treatment therefore needs to consider both oncological characteristics and patient factors, rather than assuming that one approach is universally superior.

The more useful question is:

“Which curative treatment strategy is most appropriate for this particular cancer and this particular patient?”

Where Does Robotic Radical Cystectomy Fit In?

Once radical cystectomy has been selected as the appropriate treatment, another question arises:

Should the operation be performed robotically or through an open approach?

Robot-assisted radical cystectomy allows the operation to be performed through smaller abdominal incisions using a robotic surgical platform.

The fundamental cancer operation, however, remains the same:

Removal of the bladder + appropriate pelvic lymph-node dissection + urinary diversion.

Robotic technology is therefore a surgical approach, not a different cancer treatment.

The decision to undergo cystectomy should first be made on oncological grounds. Only then should the most appropriate surgical approach be considered.

What Happens to Urine After Radical Cystectomy?

Because the bladder is removed, another method of storing or draining urine must be created.

Common options include:

Ileal Conduit

A short segment of intestine is connected to the ureters and brought to the abdominal wall as a stoma. Urine drains continuously into an external appliance.

Orthotopic Neobladder

In selected patients, intestine can be used to construct a reservoir connected to the urethra, allowing urine to pass through the natural urinary passage.

The appropriate urinary diversion depends upon multiple factors including cancer characteristics, kidney function, general health, anatomy and patient preference.

Does Every Patient With MIBC Receive the Same Treatment?

No.

Two patients with apparently similar bladder cancers may ultimately receive different treatment recommendations.

For example, treatment may be influenced by:

Cancer factors: stage, histology, tumour location, hydronephrosis, carcinoma in situ and lymph-node involvement.

Patient factors: age, kidney function, cardiac status, hearing, neuropathy, performance status and other medical conditions.

Treatment factors: cisplatin eligibility, feasibility of complete TURBT, suitability for radiotherapy and ability to undergo major surgery.

Patient priorities: willingness to undergo urinary diversion, preference regarding bladder preservation and ability to comply with long-term surveillance.

Modern bladder cancer management is therefore increasingly based on individualised treatment planning.

Why Is Multidisciplinary Assessment Important?

MIBC sits at the intersection of several cancer treatments:

Surgery + systemic therapy + radiation oncology + pathology + imaging.

A patient who sees only a surgeon may not fully explore bladder preservation.

Conversely, a patient seeking bladder preservation needs to understand when radical cystectomy may provide a more appropriate oncological strategy.

Similarly, proceeding immediately to surgery without considering appropriate perioperative systemic therapy may miss an important component of treatment in eligible patients.

The objective of multidisciplinary assessment is therefore not simply to decide whether the bladder can be removed, but to determine the complete sequence of treatment most appropriate for that patient.

Muscle-Invasive Bladder Cancer Treatment in Lucknow

For patients diagnosed with T2 or muscle-invasive bladder cancer after TURBT, the next treatment decision is particularly important.

At Uro-Onco Connect, Lucknow, evaluation of muscle-invasive bladder cancer focuses on the complete cancer treatment pathway:

Review of TURBT pathology → accurate staging → assessment for systemic treatment → radical cystectomy versus bladder preservation → selection of urinary diversion where required → postoperative treatment and surveillance.

For patients in whom radical cystectomy is appropriate, suitability for robot-assisted radical cystectomy with pelvic lymph-node dissection can be assessed.

Equally importantly, patients who may be candidates for bladder-preserving trimodality treatment should have that option considered rather than assuming that every diagnosis of muscle-invasive bladder cancer automatically requires bladder removal.

The objective is not to select a particular technology first.

The objective is to select the appropriate cancer treatment first.

About Dr. Anshuman Singh

Dr. Anshuman Singh
M.S., M.Ch. Urology (Gold Medalist)
Fellowship – Uro-Oncology & Robotic Surgery (USI, Intuitive Certified)
Visiting Fellow – Robotic Uro-Oncology (Fundació Puigvert, Spain)
Clinical Observer – Robotic Pelvic Oncology (University College London Hospitals, London) Vice Chairperson – Uro-Oncology & Robotic Surgery
Chandan Cancer Institute, Chandan Hospital
Lucknow

Dr. Anshuman Singh is a Uro-Oncology and Robotic Surgery specialist in Lucknow, with dedicated training in the management of urological cancers. His clinical practice focuses on bladder cancer, prostate cancer, kidney cancer, testicular cancer, penile cancer and other complex urological malignancies, with particular emphasis on uro-oncological and robot-assisted surgery.

Patients newly diagnosed with muscle-invasive bladder cancer, those advised radical cystectomy, or patients seeking a second opinion regarding bladder preservation versus bladder removal can undergo comprehensive uro-oncology evaluation to determine the appropriate treatment pathway.